Anavex Life Sciences Corp (AVXL)

[abew4me]

All I know is that my investment in Anavex just got a BIG BOOST of confidence when Deep Track Capital plunked down $50 Million to buy shares in AVXL.

The executives at Deep Track Capital spent a lot of time and money researching Anavex before they invested all of that money.

It's what professional investors call smart money.

Typically, retail investors are the last ones to know where the smart money is invested. This time, we beat them to the punch.

smart money |smärt 'm?ne|
(noun)

money invested by experts/professionals after extensive research



Anavex announced that it has entered into a definitive purchase agreement with Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock.

(( IMO Anavex could not have found a better buyer of it's stock. This will be a long and strong hold. Note the education level and business experiences, mostly Doctors and PhDs. The fact that with their elite background that they invested in Anavex is a positive validation for Anavex. ))

Deep Track Capital which Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.

Who we are:

David Kroin Founder and Chief Investment Officer; David earned a Bachelor of Science in Actuarial Mathematics from the University of Michigan and serves on the leadership council of the University’s Life Sciences Institute. He has served on numerous boards of public and private health care companies (including, CellCarta, Cytovance, CorEvitas, Mediatech, ProPT, Biodel, APT, Gentium and US Bioservices

Rael Mazansky, MD/MBA Managing Director; his Medical Doctorate from the Columbia University College of Physicians and Surgeons and a Master’s Degree in Business Administration from the Columbia University Graduate School of Business.

Steven Breazzano, Ph.D. Principal; Steve earned a Master of Science in Chemistry and a Bachelor of Arts in both Chemistry and Biochemistry from Brandeis University and his Ph.D. in Chemistry from The Scripps Institute

Rebecca Luse Principal; Rebecca earned a Bachelor of Science in Biochemistry and Mathematics from Indiana University.

Gerard Smith, MD/MBA Principal; Gerard earned both his Medical Doctorate and Master’s in Business Administration from University of Miami and a Bachelor of Science in Psychology from Virginia Commonwealth University. Following medical school, Gerard was a resident physician in Anesthesiology at the VCU Health System prior to joining the equity research department at Leerink Partners (now SVB Leerink), where he became a Vice President covering biotechnology companies for two years.

Aaron Hakim, MD Exclusive Consultant; Aaron Hakim, MD is a resident physician in internal medicine at Beth Israel Deaconess Medical Center and a clinical fellow at Harvard Medical School. Previously, Aaron was a Vice President at Great Point Partners, a biotechnology-focused investment fund where he worked with David for seven years. His research has appeared in peer reviewed journals including the Journal of Hepatology, the Journal of the American Medical Association, and the Journal of Biological Chemistry. Aaron earned his medical degree with honors at Yale School of Medicine and graduated summa cum laude from Yale University with an M.S. in Molecular Biology and a B.S. in Economics and Molecular Biology.

Rod Lim, Ph.D. Associate; Prior to joining Deep Track, Rod was a Vice President in the healthcare investment banking group at Jeffries Financial Group, where focused exclusively on biopharmaceutical companies for approximately two years and prior to that, worked for a year and a half in the business development team at Samsung Bioepis, evaluating venture investments for Samsung’s biotech fund, as well as in-licensing opportunities. Rod has a Ph. D. and an M.S. in Neurobiology/CNS from the California Institute of Technology, and a B.S. in Molecular Biology and a M.S in Cancer Biology from the University of California, San Diego.

Chris Margono, MD Associate: Chris earned his Medical Doctorate from the University of California at San Francisco (UCSF) where was awarded the school of medicine dean’s research prize, and a Bachelor of Science in Chemistry from University of California at Riverside. Following his MD., Chris spent almost two years as a consultant at Simon-Kucher & Partners focusing on the health care and life sciences sector. Previously he was a summer intern at Aquillo Capital Management, a biotechnology focused hedge fund.

Janet Okogbaa, MD Associate; Janet earned her Medical Doctorate with a scholarly concentration in bioengineering and healthcare investing from Stanford University, and a Bachelor of Arts in Human Biology from Stanford University.

Timothy Zhou, Associate: Prior to joining Deep Track Capital, Tim was an Associate at Novo Ventures focused on public and crossover investments in the biotech and medical technology sectors. Previously, he worked at Bank of America Merrill Lynch in the healthcare investment banking group, where he advised public and private biotech and pharmaceutical companies on strategic and financing matters. Tim earned a Bachelor of Science in Bioengineering from the University of Pennsylvania and a Bachelor of Science in Economics (Concentration in Finance) from the Wharton School.

Janet Okogbaa, MD, Associate; Janet earned her Medical Doctorate with a scholarly concentration in bioengineering and healthcare investing from Stanford University, and a Bachelor of Arts in Human Biology from Stanford University. Following her MD., Janet spent two years as an investment banking associate at Lazard Freres, focusing on the health care and life sciences sector, and the past year and one half as a buyside research analyst at Millennium Management focusing on biotechnology

Timothy Zhou, Associate; Prior to joining Deep Track Capital, Tim was an Associate at Novo Ventures focused on public and crossover investments in the biotech and medical technology sectors. Previously, he worked at Bank of America Merrill Lynch in the healthcare investment banking group, where he advised public and private biotech and pharmaceutical companies on strategic and financing matters. Tim earned a Bachelor of Science in Bioengineering from the University of Pennsylvania and a Bachelor of Science in Economics (Concentration in Finance) from the Wharton School.

Plus 4 more.
Link: https://www.deeptrackcapital.com/team